PATENT CLAIM ANALYSIS

Application Number: 16360811
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-09
Patent Classification: ["514", "235800"]

Abstract:
Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.

Claim (Index 5):
The compound of formula (I) according to  claim 1 , wherein:\n R 1  is hydrogen, R 2 /R 3  is independently hydrogen, fluorine, chlorine, bromine, cyano, hydroxy, CF 3 , \u2014O\u2014CH 3  or \u2014O\u2014CH 2 \u2014CF 3 , R 4  is independently of each other hydrogen, fluorine, chlorine, bromine or iodine, cyano, NO 2 , hydroxy, \u2014CH 3 , \u2014C 3 H 7 , cyclopropyl, 1-propenyl, \u2014C\u2261CH, \u2014CF 3 , \u2014CH 2 \u2014OH, \u2014CH 2 \u2014CH 2 \u2014OH, \u2014C(CH 3 ) 2 \u2014OH, \u2014CH 2 \u2014C(CH 3 ) 2 \u2014OH, \u2014C(CH 3 ) 2 \u2014CH 2 \u2014OH, \u2014OCH 3 , \u2014O\u2014CH 2 \u2014CH 3 , \u2014OCF 3 , \u2014OCF 2 H, \u2014OCH 2 CF 3 , \u2014O\u2014(CH 2 )\u2014O\u2014C(O)CH 3 , \u2014C(O)CH 3 , \u2014COOH, \u2014C(O)OCH 3 , \u2014C(O)OC 2 H 5 , \u2014C(O)OC(CH 3 ) 3 , \u2014CH 2 \u2014COOH, \u2014CH 2 \u2014COOC 2 H 5 , \u2014C(CH 3 ) 2 \u2014COOC 2 H 5 , \u2014C(O)NH 2 , \u2014C(O)NH(CH 3 ), \u2014C(O)N(CH 3 ) 2 , \u2014C(O)NH\u2014(CH 2 ) 2 \u2014OH, \u2014C(O)\u2014(N-morpholinyl), \u2014SO 2 \u2014NH-cyclopropyl, \u2014SO 02 \u2014(N-morpholino), NH 2 , NH\u2014C(O)(CH 3 ), 5-methyl-oxa-diazol-3-yl, N-pyrrolyl, N-pyrazolyl, \u2014S\u2014CF 3 , SF 5 ,\n whereby two of R 2 , R 3 (R 4 ) n , when positioned ortho to each other, form together \u2014O\u2014CH 2 \u2014CH 2 \u2014CH 2 \u2014O\u2014, \u2014O\u2014CH 2 \u2014CH 2 \u2014, \u2014(CH 3 )C\u2550CH\u2014(C\u2550O)\u2014O\u2014, \u2014CH 2 \u2014(C\u2550O)\u2014O\u2014, \u2014(CH 2 ) 2 \u2014(C\u2550O)\u2014NH\u2014, which together with the two carbon atoms to which they are attached form a 5-, 6- or 7-membered ring, \n n is 0, 1, 2, 3, R 6  is hydrogen, hydroxy, cyano, \u2014O-cyclopropyl, \u2014OCH 3 , \u2014OCF 3 , \u2014OCF 2 H, \u2014OCH 2 CF 3 , \u2014O(CH 2 ) 2 \u2014OH, \u2014O\u2014(CH 2 ) 2 \u2014NH 2 , \u2014O(CH 2 ) 2 \u2014N(CH 3 ) 2 , \u2014O\u2014(CH 2 ) 2 \u2014O\u2014CH 3 , \u2014O\u2014(CH 2 ) 2 \u2014O(CH 2 ) 2 \u2014OH, \u2014O\u2014CH 2 \u2014CH(OH)\u2014CH 2 OH, \u2014O\u2014CH 2 \u2014CH(OH)\u2014CH 2 \u2014NH\u2014C(O)OC(CH 3 ) 3 , \u2014OCH 2 \u2014COOH, \u2014O\u2014CH 2 \u2014COOC 2 H 5 , C(O)NH 2 , \u2014O\u2014CH 2 \u2014C(O)-(3-fluoro-N-azetidine), \u2014OCH 2 \u2014C(O)-(3,3-difluoro-N-azetidine), \u2014O\u2014CH 2 \u2014CH(OH)\u2014CH 2 \u2014N-piperidinyl, \u2014O(CH 2 ) 2 (morpholine-4-yl), \u2014O\u2014CH 2 -(morpholine-2-yl), \u2014O\u2014CH 2 -(morpholine-2-yl-4-tert-butoxycarboxylate), \u2014O\u2014CH 2 -(pyrrolidin-2-one-5-yl), \u2014O\u2014(CH 2 ) 2 \u2014S\u2014CH 3 , \u2014O\u2014(CH 2 ) 2 \u2014SO\u2014CH 3 , \u2014O\u2014(CH 2 ) 2 \u2014SO 2 \u2014CH 2 , \u2014O\u2014CH 2 \u2014SO 2 NH 2 , \u2014SO 2 \u2014CH(CH 3 ) 2 , \u2003whereby is the point of attachment,\n O\u2014(CH 2 ) 2 -tetrazolyl, \u2014O\u2014CH 2 -tetrazolyl, \u2014O-pyridine-4-yl, \u2014O-(3-cyano-pyridine-4-yl), or \u2014O\u2014CH 2 -(oxadiazole)-CH 2 \u2014O\u2014CH 3 , \n R 7  is hydrogen, methyl, difluoromethyl, hydroxyethyl, \u2003whereby * is the point of attachment,\n \u2014(CH 2 ) 2 -tetrazolyl, pyridine-4-yl, \u2014C(O)-tetrahydropyran-4-yl, \u2014C(O)\u2014CH 2 \u2014O\u2014CH 3 , \u2014C(O)CH 3 , \u2014C(O)CH 2 \u2014O\u2014(CH 2 ) 2 \u2014O\u2014CH 3 , C(O)OCH 2 \u2014CH\u2550CH 2 , or benzyl which is optionally substituted one or more times with fluorine, chlorine, bromine, cyano, methyl, difluoromethyl, methoxy, ethoxy, difluormethoxy, trifluoromethoxy, \u2014O\u2014CH 2 \u2014CF 3 , \u2014C(O)OCH 3 , or \n optionally, R 6  and R 7  together with the nitrogen atom to which R 7  is attached form a 6-membered ring which may contain one further heteroatom selected from the group consisting of O, S, N and which in addition is optionally substituted by \u2014CH 2 \u2014OH or \u2014CH 2 \u2014NH\u2014CHO \n R 8  is hydrogen, fluorine, hydroxy, cyano, CH 3 , CF 3 , CH 2 \u2014OH, OCH 3 , C(O)OH, C(O)OCH 3 , C(O)OC 2 H 5 , C(O)O(CH 2 ) 2 \u2014OH, C(O)NH 2 , C(O)NHCH 3 , m is 0, 1 or 2 or an N-oxide, a salt, a tautomer or a stereoisomer thereof, or a salt of said N-oxide, tautomer or stereoisomer.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 99.0
- Lexical Diversity: 1.09091
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14350160', '14365895', '14400315', '14900599', '15032957']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8440039011559061
- 35 USC 102 Novelty (BERT): 0.6140320879253167
- Combined Prediction Score: 0.8210067198328471
- Mean Citation Score: 480.713422
- Max Citation Score: 558.1653
- Similarity Product: 513.8109096688809

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test